- Home
- BLRX vs BIAF Comparison
BLRX vs BIAF Comparison
Compare BLRX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- BIAF
- Stock Information
- Founded
- BLRX 2003
- BIAF 2014
- Country
- BLRX Israel
- BIAF United States
- Employees
- BLRX N/A
- BIAF N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BLRX Health Care
- BIAF Health Care
- Exchange
- BLRX Nasdaq
- BIAF Nasdaq
- Market Cap
- BLRX 10.3M
- BIAF 12.2M
- IPO Year
- BLRX 2011
- BIAF 2022
- Fundamental
- Price
- BLRX $2.93
- BIAF $0.48
- Analyst Decision
- BLRX Buy
- BIAF Hold
- Analyst Count
- BLRX 2
- BIAF 1
- Target Price
- BLRX $26.00
- BIAF N/A
- AVG Volume (30 Days)
- BLRX 30.2K
- BIAF 28.5M
- Earning Date
- BLRX 05-27-2025
- BIAF 05-14-2025
- Dividend Yield
- BLRX N/A
- BIAF N/A
- EPS Growth
- BLRX N/A
- BIAF N/A
- EPS
- BLRX N/A
- BIAF N/A
- Revenue
- BLRX $28,940,000.00
- BIAF $9,362,022.00
- Revenue This Year
- BLRX N/A
- BIAF N/A
- Revenue Next Year
- BLRX N/A
- BIAF $19.99
- P/E Ratio
- BLRX N/A
- BIAF N/A
- Revenue Growth
- BLRX 502.92
- BIAF 269.68
- 52 Week Low
- BLRX $2.30
- BIAF $0.24
- 52 Week High
- BLRX $35.60
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- BLRX 48.07
- BIAF 48.20
- Support Level
- BLRX $2.30
- BIAF $0.46
- Resistance Level
- BLRX $3.09
- BIAF $0.54
- Average True Range (ATR)
- BLRX 0.22
- BIAF 0.10
- MACD
- BLRX 0.06
- BIAF -0.01
- Stochastic Oscillator
- BLRX 79.33
- BIAF 10.82
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.